Streetbeat News

Products Services

RDW

Redwire shares are trading higher following the announcement that the company is finalizing integration and preparing for the delivery of two satellites for the European Space Agency's Proba-3 mission, expected later in the fourth quarter of this year.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:41 am

PFE

SGMO

The FDA has approved Pfizer's Hympavzi for hemophilia A and B, marking it as the first anti-TFPI treatment in the U.S. with a pre-filled auto-injector pen. This approval is based on successful Phase 3 trial results, and analysts expect sales to reach $300 million by 2030. Pfizer's stock showed a slight decline in premarket trading.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 11:35 am

PROK

ProKidney Corp. (NASDAQ:PROK) will present five posters, including a late-breaking clinical trial, at ASN Kidney Week 2024. The presentations will focus on their cell therapy candidate, Rilparencel, for chronic kidney disease (CKD) and its effects on patients with diabetes and advanced CKD.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:33 am

QTTB

Q32 Bio is set to present Phase 1 clinical trial results for its tissue-targeted complement inhibitor, ADX-097, at the American Society Of Nephrology Kidney Week 2024. The results from the first-in-human trial in healthy volunteers support Phase 2 dose selection and further clinical development.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:20 am

BITF

CAN

CLSK

COIN

HIVE

HUT

MARA

RIOT

Crypto-linked stocks and miners are experiencing a rise in share prices due to an increase in Bitcoin's value.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:14 am

RDHL

RedHill Biopharma's opaganib has been selected by BARDA for joint development and funding as a medical countermeasure for Ebola virus disease. This collaboration aims to advance opaganib towards potential FDA approval, following positive results in U.S. Army-funded studies. The drug shows promise as a mutation-resistant antiviral and anti-inflammatory treatment, addressing the urgent need for effective Ebola therapies.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:13 am

BLCO

Bausch + Lomb announced that the FDA has approved its enVista Envy Full Range Of Vision Intraocular Lens (IOL). The product will be available in the U.S. on a limited basis soon, with broader availability expected in 2025. The company is also pursuing regulatory approvals in other markets.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:10 am

BLCO

Bausch + Lomb has received FDA approval for its enVista Envy Full Vision Intraocular Lens range, potentially boosting its market position in the ophthalmic sector.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:09 am

BCRX

BioCryst Pharmaceuticals' ORLADEYO shows significant reductions in healthcare resource utilization for hereditary angioedema patients, including fewer hospitalizations and emergency visits. The study will be presented at the AMCP Nexus 2024 meeting.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:08 am

NOW

ServiceNow is investing $1.5 billion to expand its UK operations, focusing on office space, workforce growth, and AI innovation. The company plans to implement AI through domain-specific LLMs in UK data centers and reskilling programs for British workers.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:07 am